Sickle cell trait knowledge and health literacy in caregivers who receive in ‐person sickle cell trait education

ConclusionOur results suggest that caregivers’ baseline SCT knowledge is low, improves with in‐person education but may decline with time. Caregivers who do not achieve high SCT knowledge after education had lower health literacy and baseline knowledge. Future studies should determine if adapting in‐person education to caregivers’ health literacy and knowledge levels results in high and sustained SCT knowledge among all caregivers and more individuals who know their SCT status. Only 16% of individuals with sickle cell trait know their status. This prospective study of caregivers of infants with sickle cell trait found that caregivers’ baseline sickle cell trait knowledge is low and improves with in‐person education, but low health literacy and baseline sickle cell trait knowledge are associated with poor caregiver sickle cell knowledge achievement. Our study identifies specific areas of the education that are modifiable and could result in higher sickle cell trait knowledge among caregivers.
Source: Molecular Genetics & Genomic Medicine - Category: Genetics & Stem Cells Authors: Tags: Original Article Source Type: research

Related Links:

Novartis announced it won U.S. FDA approval for its experimental sickle cell disease drug, Adakveo.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Crizanlizumab binds to P-selectin, a cell adhesion protein that plays a central role in the multicellular interactions that can lead to vaso-occlusion in sickle cell disease.FDA Approvals
Source: Medscape Pediatrics Headlines - Category: Pediatrics Tags: Hematology-Oncology News Alert Source Type: news
U.S. regulators have approved a new medicine that can help manage extremely painful sickle cell disease flare-ups
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Basel, November 15, 2019– Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Oncology Newsburst
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
Authors: Pijnenburg L, Felten R, Javier RM Abstract Avascular necrosis is an ischemic or cytotoxic necrosis of epiphyseal bone, responsible for joint pain, altered life quality and frequently affecting young patients. Avascular necrosis can be unifocal or multifocal, underlining the possibility of a systemic origin. Avascular necrosis involves the femoral head in more than 75% of cases. Although avascular necrosis is irreversible, many risk factors must be sought, including corticosteroid treatment, hypercholesterolemia, sickle cell disease or alcohol abuse. MRI imaging is the main exploration for the diagnostic an...
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
Today, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis - a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells - for patients age 16 years and older.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Healthy red blood cells (RBCs) deform readily in response to shear stress in the circulation, facilitating their efficient passage through capillaries. RBCs also export vasoactive mediators in response to deformation and other physiological and pathological stimuli. Deoxygenation of RBC hemoglobin leads to the export of vasodilator and antiadhesive S-nitrosothiols (SNOs) and adenosine triphosphate (ATP) in parallel with oxygen transport in the respiratory cycle. Together, these mediated responses to shear stress and oxygen offloading promote the efficient flow of blood cells and in turn optimize oxygen delivery. In disease...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
More News: Children | Education | Genetics | Sickle Cell Anemia | Study | Universities & Medical Training